123 related articles for article (PubMed ID: 32931454)
1. Identification of a cullin5-RING E3 ligase transcriptome signature in glioblastoma multiforme.
Zheng S; Li Z
Aging (Albany NY); 2020 Sep; 12(17):17380-17392. PubMed ID: 32931454
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme.
Zheng S; Tao W
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804433
[TBL] [Abstract][Full Text] [Related]
3. Integrating cullin2-RING E3 ligase as a potential biomarker for glioblastoma multiforme prognosis and radiosensitivity profiling.
Zheng S; Wu Y; Li Z
Radiother Oncol; 2021 Jan; 154():36-44. PubMed ID: 32918970
[TBL] [Abstract][Full Text] [Related]
4. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.
Zhou H; Miki R; Eeva M; Fike FM; Seligson D; Yang L; Yoshimura A; Teitell MA; Jamieson CA; Cacalano NA
Clin Cancer Res; 2007 Apr; 13(8):2344-53. PubMed ID: 17438093
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
7. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.
Zhang W; Zhang J; Yan W; You G; Bao Z; Li S; Kang C; Jiang C; You Y; Zhang Y; Chen CC; Song SW; Jiang T
Cancer; 2013 Feb; 119(4):814-24. PubMed ID: 22990979
[TBL] [Abstract][Full Text] [Related]
8. Establishment and External Validation of a Hypoxia-Derived Gene Signature for Robustly Predicting Prognosis and Therapeutic Responses in Glioblastoma Multiforme.
Wang K; Lu Y; Liu Z; Diao M; Yang L
Biomed Res Int; 2022; 2022():7858477. PubMed ID: 35155681
[TBL] [Abstract][Full Text] [Related]
9. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
Ventero MP; Fuentes-Baile M; Quereda C; Perez-Valeciano E; Alenda C; Garcia-Morales P; Esposito D; Dorado P; Manuel Barbera V; Saceda M
PLoS One; 2019; 14(2):e0212581. PubMed ID: 30811476
[TBL] [Abstract][Full Text] [Related]
11. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
12. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.
Yu Z; Yang H; Song K; Fu P; Shen J; Xu M; Xu H
Front Oncol; 2022; 12():938679. PubMed ID: 35982954
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
14. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
[TBL] [Abstract][Full Text] [Related]
15. SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.
Dai L; Tao Y; Shi Z; Liang W; Hu W; Xing Z; Zhou S; Guo X; Fu X; Wang X
Front Oncol; 2022; 12():881801. PubMed ID: 35600392
[TBL] [Abstract][Full Text] [Related]
16. SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients.
Feng Y; Wang Z; Bao Z; Yan W; You G; Wang Y; Hu H; Zhang W; Zhang Q; Jiang T
PLoS One; 2014; 9(3):e91829. PubMed ID: 24633048
[TBL] [Abstract][Full Text] [Related]
17. Identification of
Lin H; Yang Y; Hou C; Zheng J; Lv G; Mao R; Xu P; Chen S; Zhou Y; Wang P; Zhou D
Genet Test Mol Biomarkers; 2021 May; 25(5):334-345. PubMed ID: 33970702
[No Abstract] [Full Text] [Related]
18. Thrombospondin-1 is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
Oncol Lett; 2021 Jan; 21(1):22. PubMed ID: 33240428
[TBL] [Abstract][Full Text] [Related]
19. A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
Fatai AA; Gamieldien J
BMC Cancer; 2018 Apr; 18(1):377. PubMed ID: 29614978
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Zhao L; Zhang J; Xuan S; Liu Z; Wang Y; Zhao P
Front Cell Dev Biol; 2021; 9():600506. PubMed ID: 33614641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
